Sign In
Buy AGNPF
$0.248
-0.0513 (-17.12%)
At Close: Jul 31, 2026
Algernon Pharmaceuticals submits pre-investigational new drug meeting request with US FDA for its DMT stroke research program
09:57am, Wednesday, 17'th Mar 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) has started formal communication with the US regulator, the Food and Drug Administration (FDA), over its previously announced stroke clin
Algernon Pharmaceuticals updates on timing of topline results for Ifenprodil trial
08:57am, Thursday, 11'th Mar 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (FR:AGW) (OTCQB:AGNPF) said it expects to report the topline results for the Phase 2b part of its Phase 2b/3 coronavirus (COVID-19) trial of its Ifenprodil treat
Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil
07:41am, Thursday, 11'th Mar 2021
VANCOUVER, British Columbia, March 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharma
Algernon Pharmaceuticals Inc. (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF), said it has increased and completed its previously announced non-brokered private placement of units raising gross proceeds of C$2,815
Algernon Pharmaceuticals Announces Increase and Close of Private Placement
07:31pm, Friday, 05'th Mar 2021
VANCOUVER, British Columbia, March 05, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmac
Algernon Pharmaceuticals launches non-brokered private placement of 10,800,000 units for total proceeds of C$2,700,000
09:39am, Wednesday, 03'rd Mar 2021
Algernon Pharmaceuticals Inc. (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF), a clinical-stage pharmaceutical development company has announced a non-brokered private placement of 10,800,000 units for total procee
VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharma
Algernon Pharmaceuticals Announces Private Placement
10:18pm, Tuesday, 02'nd Mar 2021
VANCOUVER, British Columbia, March 02, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmac
Algernon Pharmaceuticals contracts Hammersmith Medicines Research for Phase 1 DMT stroke study; adds to leadership
09:04am, Monday, 01'st Mar 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) said its Phase 1 study on the psychedelic compound DMT to treat stroke will be carried out by London-based contract research organization
Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer
07:00am, Monday, 01'st Mar 2021
VANCOUVER, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmac
Algernon Pharmaceuticals selects Dalton Pharma Services to synthesize DMT for its stroke studies
09:41am, Friday, 19'th Feb 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) said Friday it had awarded a manufacturing contract to Dalton Pharma Services to synthesize N,N-Dimethyltryptamine (DMT), a hallucinogen
Algernon Pharmaceuticals updates on progress of Phase 2b final data from coronavirus trial
09:08am, Wednesday, 17'th Feb 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW), the drug repurposing company, updated on the progress of releasing its final data set from the Phase 2b part of its Phase 2b/3 trial t
Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data
07:48am, Wednesday, 17'th Feb 2021
VANCOUVER, British Columbia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace
Algernon targeting psychedelic drug DMT for stroke program
05:51am, Monday, 15'th Feb 2021
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) is one of three emerging companies that will present at Proactive's virtual investor conference on Tuesday, February 16. Hosted by Proactive's Chri
BTV News Alert Video: Algernon Pharmaceuticals Inc. - Trial Complete for COVID-19 Treatment
02:37pm, Thursday, 11'th Feb 2021
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2021) - Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) - The company has concluded a trial for Ifenprodil and is expecting to repor
